

Supplementary Online Content

Salazar MC, Rosen JE, Wang Z, et al. Association of delayed adjuvant chemotherapy with survival after lung cancer surgery. *JAMA Oncol*. Published online January 5, 2016. doi:10.1001/jamaoncol.2016.5829.

eTable 1. Patient Characteristics of the Propensity-Matched Pairs of Surgery Only and “Earlier” Adjuvant Chemotherapy Group.

eTable 2. Patient Characteristics of the Propensity-Matched Pairs of Surgery Only and “Reference Interval” Adjuvant Chemotherapy Group.

eTable 3. Patient Characteristics of the Propensity-Matched Pairs of Surgery Only and “Later” Adjuvant Chemotherapy Group.

eTable 4. Cox Proportional Hazards Model of Adjuvant Chemotherapy Patients “Landmarked” at 120 Days After Surgery.

eTable 5. Multivariate Logistic Regression Modeling of Predictors of “Later” (>56 Days) Initiation of Adjuvant Chemotherapy.

This supplementary material has been provided by the authors to give readers additional information about their work.

Supplement

Elements Included

1. eTable 1. Patient Characteristics of the Propensity-Matched Pairs of Surgery Only and “Earlier” Adjuvant Chemotherapy Group.
2. eTable 2. Patient Characteristics of the Propensity-Matched Pairs of Surgery Only and “Reference Interval” Adjuvant Chemotherapy Group.
3. eTable 3. Patient Characteristics of the Propensity-Matched Pairs of Surgery Only and “Later” Adjuvant Chemotherapy Group.
4. eTable 4. Cox Proportional Hazards Model of Adjuvant Chemotherapy Patients “Landmarked” at 120 Days After Surgery.
5. eTable 5. Multivariate Logistic Regression Modeling of Predictors of “Later” (>56 Days) Initiation of Adjuvant Chemotherapy.

eTable 1. Patient Characteristics of the Propensity-Matched Pairs of Surgery Only and “Earlier” Adjuvant Chemotherapy Group.

Characteristic	Surgery Only (N = 3,277)	“Earlier” (N = 3,277)	<i>p</i> Value
	n (%)	n (%)	
Facility Type			
Academic/Research Program	904 (28)	921 (28)	0.64
Non-Academic Program ^a	2,373 (72)	2,356 (72)	
Facility Location			
New England	173 (5)	163 (5)	0.98
Middle Atlantic	356 (11)	378 (12)	
South Atlantic	799 (24)	808 (25)	
East North Central	774 (24)	759 (23)	
East South Central	277 (8)	287 (9)	
West North Central	340 (10)	343 (10)	
West South Central	202 (6)	193 (6)	
Mountain	121 (4)	124 (4)	
Pacific	235 (7)	222 (7)	
Age, mean (SD), years	63 (11)	63 (9)	0.57
Sex			
Male	1,811 (55)	1,821 (56)	0.80
Female	1,466 (45)	1,456 (44)	
Race			
White	2,932 (89)	2,953 (90)	0.39
Non-White	345 (11)	324 (10)	
Hispanic Origin			
Non-Hispanic	2,943 (90)	2,947 (90)	0.82
Hispanic Origin	67 (2)	60 (2)	
Unknown	267 (8)	270 (8)	
Insurance Status			
Not Insured	87 (3)	79 (2)	0.99
Private Insurance	1,470 (45)	1,492 (46)	
Characteristic	Surgery Only n (%)	“Earlier” n (%)	<i>p</i> Value
Medicaid	171 (5)	169 (5)	
Medicare	1,469 (45)	1,457 (44)	
Other Government	40 (1)	40 (1)	
Status Unknown	40 (1)	40 (1)	
Income^b			

< \$38,000	578 (18)	610 (19)	0.62
\$38,000-\$47,999	856 (26)	826 (25)	
\$48,000-\$62,999	947 (29)	915 (28)	
63,000 +	839 (26)	872 (27)	
Unknown	57 (2)	54 (2)	
Education^c			
≥ 21%	500 (15)	507 (15)	0.88
13%-20.9%	868 (26)	891 (27)	
7%-12.9%	1,168 (36)	1,129 (34)	
< 7%	685 (21)	697 (21)	
Unknown	56 (2)	53 (2)	
Area of Residence^b			
Metropolitan	2,509 (77)	2,526 (77)	0.78
Urban	555 (17)	551 (17)	
Rural	102 (3)	88 (3)	
Unknown	111 (3)	112 (3)	
Charlson-Deyo Score			
0	1,765 (54)	1,771 (54)	0.82
1	1,132 (35)	1,142 (35)	
2+	380 (12)	364 (11)	
Year of Diagnosis			
2004	268 (8)	275 (8)	0.99
2005	408 (12)	392 (12)	
2006	436 (13)	414 (13)	
Characteristic	Surgery Only	“Earlier”	P
	n (%)	n (%)	Value
2007	349 (11)	358 (11)	
2008	336 (10)	347 (11)	
2009	330 (10)	329 (10)	
2010	333 (10)	327 (10)	
2011	375 (11)	385 (12)	
2012	442 (13)	450 (14)	
Primary Site			
Upper Lobe	1,893 (58)	1,905 (58)	0.99
Middle Lobe	121 (4)	124 (4)	
Lower Lobe	1,134 (35)	1,121 (34)	
Overlapping Lesion	68 (2)	70 (2)	
Lung, NOS	61 (2)	57 (2)	
Tumor Laterality			

Right	1,806 (55)	1,803 (55)	0.95
Left	1,468 (45)	1,470 (45)	
Unknown	~	~	
Tumor Histological Type			
Adenocarcinoma	1,890 (58)	1,888 (58)	0.98
Squamous Cell Carcinoma	1,052 (32)	1,044 (32)	
Large Cell Carcinoma	153 (5)	156 (5)	
Other ^d	182 (6)	189 (6)	
Tumor Grade			
1	187 (6)	171 (5)	0.92
2	1,303 (40)	1,307 (40)	
3	1,578 (48)	1,596 (49)	
4	108 (3)	106 (3)	
Undetermined	101 (3)	97 (3)	
Tumor Pathologic Stage			
I	766 (23)	765 (23)	0.8
Characteristic	Surgery Only n (%)	“Earlier” n (%)	p Value
II	1,616 (49)	1,594 (49)	
III	895 (27)	918 (28)	
Tumor Size, mean (SD), cm	4.5 (3.5)	4.5 (3.4)	0.67
Type of Resection			
Lobectomy	2,865 (87)	2,892 (88)	0.31
Pneumonectomy	412 (13)	385 (12)	
Length of Inpatient Stay			
≤ 14 Days	2,917 (89)	3,213 (98)	<0.001
> 14 Days	360 (11)	64 (2)	
Readmission Within 30 Days of Discharge			
No	2,918 (89)	2,955 (90)	<0.001
Unplanned	200 (6)	102 (3)	
Planned	95 (3)	136 (4)	
Planned and Unplanned	~	~	
Unknown	60 (2)	80 (2)	
Ninety Day Mortality			
Alive > 90 days	3,078 (94)	3,226 (98)	<0.001
Died ≤ 90 days	172 (5)	41 (1)	

Unknown	27 (1)	10 (0)	
---------	--------	--------	--

SD = Standard deviation

NOS = Not otherwise specified

a = Includes Community Cancer Program, Comprehensive Community Cancer Program, Integrated Network Cancer Program and other specified types of cancer programs.

b = Based on patient's zip code area.

c = Percent of people in the patient's zip code area with no high-school diploma.

d = Non-small cell not further defined.

~ = Frequencies < 10 not reported per National Cancer Database guidelines.

All percentages might not add up to 100% due to approximation.

eTable 2. Patient Characteristics of the Propensity-Matched Pairs of Surgery Only and “Reference Interval” Adjuvant Chemotherapy Group.

Characteristic	Surgery Only (N = 4,967)	“Reference Interval” (N = 4,967)	<i>p</i> Value
	n (%)	n (%)	
Facility Type			
Academic/Research Program	1,679 (34)	1,694 (34)	0.75
Non-Academic Program ^a	3,288 (66)	3,273 (66)	
Facility Location			
New England	278 (6)	292 (6)	0.98
Middle Atlantic	661 (13)	660 (13)	
South Atlantic	1,164 (23)	1,172 (24)	
East North Central	1,074 (22)	1,066 (21)	
East South Central	532 (11)	505 (10)	
West North Central	482 (10)	490 (10)	
West South Central	286 (6)	274 (6)	
Mountain	147 (3)	144 (3)	
Pacific	343 (7)	364 (7)	
Age, mean (SD), years	63 (11)	64 (9)	0.41
Sex			
Male	2,647 (53)	2,666 (54)	0.70
Female	2,320 (47)	2,301 (46)	
Race			
White	4,318 (87)	4,330 (87)	0.72
Non-White	649 (13)	637 (13)	
Hispanic Origin			
Non-Hispanic	4,496 (91)	4,496 (91)	0.62
Hispanic Origin	101 (2)	89 (2)	
Unknown	370 (7)	382 (8)	
Insurance Status			
Not Insured	143 (3)	130 (3)	0.80
Characteristic	Surgery Only n (%)	“Reference Interval” n (%)	<i>p</i> Value
Private Insurance	2,044 (41)	2,085 (42)	
Medicaid	295 (6)	273 (5)	
Medicare	2,363 (48)	2,367 (48)	

Other Government	51 (1)	46 (1)	
Status Unknown	71 (1)	66 (1)	
Income^b			
< \$38,000	980 (20)	964 (19)	0.98
\$38,000-\$47,999	1,244 (25)	1,243 (25)	
\$48,000-\$62,999	1,368 (28)	1,366 (28)	
63,000 +	1,281 (26)	1,303 (26)	
Unknown	94 (2)	91 (2)	
Education^c			
≥ 21%	755 (15)	732 (15)	0.89
13%-20.9%	1,456 (29)	1,430 (29)	
7%-12.9%	1,663 (33)	1,693 (34)	
< 7%	1,003 (20)	1,024 (21)	
Unknown	90 (2)	88 (2)	
Area of Residence^b			
Metropolitan	3,789 (76)	3,788 (76)	0.96
Urban	851 (17)	856 (17)	
Rural	132 (3)	137 (3)	
Unknown	195 (4)	186 (4)	
Charlson-Deyo Score			
0	2,653 (53)	2,649 (53)	0.38
1	1,702 (34)	1,746 (35)	
2+	612 (12)	572 (12)	
Year of Diagnosis			
2004	343 (7)	344 (7)	0.97
2005	512 (10)	478 (10)	
Characteristic	Surgery Only n (%)	“Reference Interval” n (%)	p Value
2006	522 (11)	545 (11)	
2007	536 (11)	530 (11)	
2008	556 (11)	565 (11)	
2009	486 (10)	503 (10)	
2010	648 (13)	634 (13)	
2011	661 (13)	653 (13)	
2012	703 (14)	715 (14)	
Primary Site			
Upper Lobe	2,880 (58)	2,845 (57)	0.97
Middle Lobe	217 (4)	220 (4)	

Lower Lobe	1,639 (33)	1,669 (34)	
Overlapping Lesion	145 (3)	147 (3)	
Lung, NOS	86 (2)	86 (2)	
Tumor Laterality			
Right	2,772 (56)	2,747 (55)	0.66
Left	2192 (44)	2,216 (45)	
Unknown	~	~	
Tumor Histological Type			
Adenocarcinoma	2,707 (54)	2,740 (55)	0.83
Squamous Cell Carcinoma	1,784 (36)	1,744 (35)	
Large Cell Carcinoma	219 (4)	216 (4)	
Other ^d	257 (5)	267 (5)	
Tumor Grade			
1	275 (6)	258 (5)	0.85
2	2,022 (41)	2,041 (41)	
3	2,375 (48)	2,362 (48)	
4	116 (2)	129 (3)	
Undetermined	179 (4)	177 (4)	
Characteristic	Surgery Only n (%)	“Reference Interval” n (%)	p Value
Tumor Pathologic State			
I	1,240 (25)	1,253 (25)	0.94
II	2,428 (49)	2,428 (49)	
III	1,299 (26)	1,286 (26)	
Tumor Size, mean (SD), cm	4.6 (4.0)	4.6 (2.9)	0.49
Type of Resection			
Lobectomy	4,254 (86)	4,327 (87)	0.03
Pneumonectomy	713 (14)	640 (13)	
Length of Inpatient Stay			
≤ 14 Days	4,408 (89)	4,814 (97)	<0.001
> 14 Days	559 (11)	153 (3)	
Readmission Within 30 Days of Discharge			

No	4,450 (90)	4,519 (91)	<0.001
Unplanned	303 (6)	133 (3)	
Planned	110 (2)	161 (3)	
Planned and Unplanned	~	~	
Unknown	97 (2)	148 (3)	
Ninety Day Mortality			
Alive > 90 days	4,654 (94)	4,907 (99)	<0.001
Died ≤ 90 days	275 (6)	44 (1)	
Unknown	38 (1)	16 (0)	

SD = Standard deviation

NOS = Not otherwise specified

a = Includes Community Cancer Program, Comprehensive Community Cancer Program, Integrated Network Cancer Program and other specified types of cancer programs.

b = Based on patient's zip code area.

c = Percent of people in the patient's zip code area with no high-school diploma.

d = Non-small cell not further defined.

~ = Frequencies < 10 not reported per National Cancer Database guidelines.

All percentages might not add up to 100% due to approximation.

eTable 3. Patient Characteristics of the Propensity-Matched Pairs of Surgery Only and “Later” Adjuvant Chemotherapy Group.

Characteristic	Surgery Only (N = 3,976)	"Later" (N = 3,976)	<i>p</i> Value
	n (%)	n (%)	
Facility Type			
Academic/Research Program	1,605 (40)	1,643 (41)	0.39
Non-Academic Program ^a	2,371 (60)	2,333 (59)	
Facility Location			
New England	241 (6)	245 (6)	0.99
Middle Atlantic	542 (14)	548 (14)	
South Atlantic	997 (25)	996 (25)	
East North Central	855 (22)	855 (22)	
East South Central	307 (8)	312 (8)	
West North Central	399 (10)	387 (10)	
West South Central	205 (5)	213 (5)	
Mountain	119 (3)	116 (3)	
Pacific	311 (8)	304 (8)	
Age, mean (SD), years	64 (11)	64 (9)	0.84
Sex			
Male	2,123 (53)	2,058 (52)	0.14
Female	1,853 (47)	1,918 (48)	
Race			
White	3,399 (85)	3,411 (86)	0.70
Non-White	577 (15)	565 (14)	
Hispanic Origin			
Non-Hispanic	3,544 (89)	3,550 (89)	0.96
Hispanic Origin	90 (2)	91 (2)	
Unknown	342 (9)	335 (8)	
Insurance Status			
Not Insured	142 (4)	142 (4)	0.96
Private Insurance	1,520 (38)	1,525 (38)	
Characteristic	Surgery Only n (%)	“Later” n (%)	<i>p</i> Value
Medicaid	272 (7)	257 (6)	
Medicare	1,958 (49)	1,976 (50)	
Other Government	45 (1)	39 (1)	
Status Unknown	39 (1)	37 (1)	

Income^b			
< \$38,000	761 (19)	765 (19)	0.88
\$38,000-\$47,999	1,042 (26)	1,016 (26)	
\$48,000-\$62,999	1,123 (28)	1,109 (28)	
63,000 +	977 (25)	1,015 (26)	
Unknown	73 (2)	71 (2)	
Education^c			
≥ 21%	685 (17)	679 (17)	0.62
13%-20.9%	1,141 (29)	1,096 (28)	
7%-12.9%	1,323 (33)	1,326 (33)	
< 7%	754 (19)	805 (20)	
Unknown	73 (2)	70 (2)	
Area of Residence^b			
Metropolitan	3,071 (77)	3,115 (78)	0.51
Urban	703 (18)	658 (17)	
Rural	62 (2)	69 (2)	
Unknown	140 (4)	134 (3)	
Charlson-Deyo Score			
0	2,038 (51)	2,084 (52)	0.11
1	1,399 (35)	1,415 (36)	
2+	539 (14)	477 (12)	
Year of Diagnosis			
2004	306 (8)	308 (8)	0.94
2005	381 (10)	373 (9)	
2006	350 (9)	381 (10)	
Characteristic	Surgery Only	“Later”	p
	(%)	(%)	Value
	n	n	
2007	441 (11)	443 (11)	
2008	481 (12)	463 (12)	
2009	473 (12)	458 (12)	
2010	478 (12)	469 (12)	
2011	535 (13)	523 (13)	
2012	531 (13)	558 (14)	
Primary Site			
Upper Lobe	2,269 (57)	2,267 (57)	0.78
Middle Lobe	183 (5)	174 (4)	
Lower Lobe	1,299 (33)	1,312 (33)	
Overlapping Lesion	138 (3)	149 (4)	
Lung, NOS	87 (2)	74 (2)	

Tumor Laterality			
Right	2,262 (57)	2,295 (58)	0.89
Left	1,707 (43)	1,675 (42)	
Unknown	~	~	
Tumor Histological Type			
Adenocarcinoma	2,067 (52)	2,057 (52)	0.95
Squamous Cell Carcinoma	1,480 (37)	1,496 (38)	
Large Cell Carcinoma	177 (4)	184 (5)	
Other	243 (6)	239 (6)	
Tumor Grade			
1	174 (4)	176 (4)	0.96
2	1,641 (41)	1,642 (41)	
3	1,915 (48)	1,902 (48)	
4	100 (3)	97 (2)	
Undetermined	146 (4)	159 (4)	
Tumor Pathologic Stage			
I	1,028 (26)	1,050 (26)	0.83
Characteristic	Surgery Only	“Later”	p
	(%)	(%)	Value
	n	n	
II	1,804 (45)	1,800 (45)	
III	1,144 (29)	1,126 (28)	
Tumor Size, mean (SD), cm	4.6 (4.3)	4.7 (3.3)	0.71
Type of Resection			
Lobectomy	3,400 (86)	3,401 (86)	0.97
Pneumonectomy	576 (14)	575 (14)	
Length of Inpatient Stay			
≤ 14 Days	3,487 (88)	3,687 (93)	<0.001
> 14 Days	489 (12)	289 (7)	
Readmission Within 30 Days of Discharge			
No	3,582 (90)	3,581 (90)	<0.001
Unplanned	240 (6)	193 (5)	
Planned	81 (2)	71 (2)	
Planned and Unplanned	~	~	
Unknown	71 (2)	126 (3)	

Ninety Day Mortality			
Alive > 90 days	3,715 (93)	3,947 (99)	<0.001
Died ≤ 90 days	226 (6)	21 (1)	
Unknown	35 (1)	~	

SD = Standard deviation

NOS = Not otherwise specified

a = Includes Community Cancer Program, Comprehensive Community Cancer Program, Integrated Network Cancer Program and other specified types of cancer programs.

b = Based on patient's zip code area.

c = Percent of people in the patient's zip code area with no high-school diploma.

d = Non-small cell not further defined.

~ = Frequencies < 10 not reported per National Cancer Database guidelines.

All percentages might not add up to 100% due to approximation.

eTable 4. Cox Proportional Hazards Model of Adjuvant Chemotherapy Patients “Landmarked” at 120 Days After Surgery.

Covariate	N	HR	LCL	UCL	p Value
Adjuvant Chemotherapy Timing					
“Reference Interval”	5,033	Ref			
“Earlier”	3,278	1.003	0.937	1.074	0.93
“Later”	3,894	1.040	0.974	1.111	0.24
Facility Type					
Academic/Research Program	4,155	Ref			
Non-Academic Program ^a	8,050	1.072	1.009	1.138	0.02
Age		1.019	1.015	1.023	<0.001
Sex					
Female	5,716	Ref			
Male	6,489	1.254	1.185	1.328	<0.001
Hispanic Origin					
Non-Hispanic	10,998	Ref			
Hispanic Origin	237	0.733	0.579	0.927	0.01
Unknown	970	0.958	0.868	1.056	0.39
Insurance Status					
Medicare	5,656	Ref			
Medicaid	698	1.187	1.039	1.356	0.01
Not Insured	346	1.020	0.845	1.232	0.83
Other Government	121	1.249	0.940	1.660	0.13
Private Insurance	5,241	0.900	0.837	0.968	0.005
Status Unknown	143	0.931	0.716	1.210	0.59
Income^b					
\$63,000+	3,222	Ref			
\$48,000-\$62,999	3,400	1.065	0.986	1.150	0.11
\$38,000-47,999	3,069	1.125	1.041	1.217	0.003
< \$38,000	2,313	1.174	1.079	1.277	<0.001
Unknown	201	2.184	1.812	2.633	<0.001
Charlson-Deyo Score					
0	6,565	Ref			
1	4,258	1.145	1.078	1.217	<0.001
2+	1,382	1.337	1.227	1.458	<0.001
Year of Diagnosis					
2004	910	Ref			
2005	1,237	0.976	0.872	1.091	0.67

2006	1,331	0.962	0.860	1.077	0.50
Covariate	N	HR	LCL	UCL	p Value
2007	1,324	0.962	0.858	1.078	0.50
2008	1,383	0.902	0.803	1.014	0.08
2009	1,280	0.899	0.795	1.016	0.09
2010	1,423	0.761	0.669	0.866	<0.001
2011	1,580	0.817	0.716	0.933	0.003
2012	1,737	0.822	0.709	0.952	0.009
Primary Site					
Upper Lobe	7,016	Ref			
Middle Lobe	519	1.162	1.016	1.328	0.03
Lower Lobe	4,087	1.164	1.097	1.235	<0.001
Overlapping Lesion	366	0.903	0.758	1.074	0.25
Lung, NOS	217	0.978	0.789	1.214	0.84
Tumor Histological Type					
Adenocarcinoma	6,754	Ref			
Squamous Cell Carcinoma	4,200	0.824	0.773	0.878	<0.001
Large Cell Carcinoma	551	1.157	1.018	1.314	0.03
Other ^c	700	1.031	0.919	1.156	0.61
Tumor Pathological Stage					
I	3,014	Ref			
II	5,860	1.605	1.485	1.735	<0.001
III	3,331	2.110	1.942	2.293	<0.001
Tumor Size		1.002	1.001	1.002	<0.001
Type of Resection					
Lobectomy	10,616	Ref			
Pneumonectomy	1,589	1.118	1.027	1.216	<0.001

NOS = Not otherwise specified

HR = Hazard ratio

LCL = Lower confidence limit

UCL = Upper confidence limit

a = Includes Community Cancer Program, Comprehensive Community Cancer Program, Integrated Network Cancer Program and other specified types of cancer programs.

b = Based on patient's zip code area.

c = Non-small cell not further defined.

eTable 5. Multivariate Logistic Regression Modeling of Predictors of “Later” (>56 Days) Initiation of Adjuvant Chemotherapy.

Covariate	N	OR	LCL	UCL	p Value
Facility Type					
Academic/Research Program	4,228	Ref			
Non-Academic Program ^a	8,245	0.692	0.617	0.777	<0.001
Facility Location					
New England	712	Ref			
Middle Atlantic	1,622	0.905	0.708	1.156	0.42
South Atlantic	3,009	0.879	0.699	1.105	0.27
East North Central	2,775	0.825	0.656	1.038	0.10
East South Central	1,113	0.658	0.497	0.870	0.003
West North Central	1,296	0.845	0.651	1.098	0.21
West South Central	682	0.818	0.612	1.092	0.17
Mountain	388	0.882	0.628	1.238	0.47
Pacific	876	0.988	0.755	1.293	0.93
Age		1.015	1.010	1.021	<0.001
Sex					
Female	5,829	Ref			
Male	6,644	0.844	0.778	0.916	<0.001
Race					
White	10,928	Ref			
Non-White	1,545	1.139	1.005	1.291	0.04
Hispanic Origin					
Non-Hispanic	11,224	Ref			
Hispanic Origin	243	1.229	0.922	1.638	0.16
Unknown	1,006	1.151	0.977	1.357	0.09
Insurance Status					
Medicare	5,812	Ref			
Private Insurance	5,328	0.885	0.797	0.984	0.02
Medicaid	709	1.248	1.031	1.512	0.02
Not Insured	354	1.467	1.144	1.882	0.003
Other Government	126	0.958	0.637	1.439	0.84
Status Unknown	144	0.739	0.495	1.104	0.14
Education^b					
<7%	2,612	Ref			
7%-12.9%	4,248	1.025	0.915	1.149	0.67

13%-20.9%	3,474	1.051	0.929	1.189	0.43
≥ 21%	1,928	1.229	1.062	1.423	0.006
Covariate	N	OR	LCL	UCL	p Value
Unknown	211	1.303	0.852	1.994	0.22
Area of Residence^c					
Metropolitan	9,642	Ref			
Urban	2,101	1.004	0.893	1.129	0.94
Rural	298	0.670	0.498	0.901	0.008
Unknown	432	0.836	0.616	1.133	0.25
Charlson-Deyo Score					
0	6,697	Ref			
1	4,352	1.083	0.991	1.183	0.08
2+	1,424	1.106	0.970	1.262	0.13
Year of Diagnosis					
2004	929	Ref			
2005	1,260	0.824	0.680	0.998	0.05
2006	1,361	0.767	0.633	0.928	0.006
2007	1,347	0.993	0.822	1.198	0.94
2008	1,397	1.033	0.857	1.245	0.73
2009	1,308	1.104	0.914	1.333	0.31
2010	1,459	0.967	0.802	1.165	0.72
2011	1,615	1.000	0.833	1.201	0.99
2012	1,797	0.908	0.758	1.088	0.30
Tumor Laterality					
Right	6,969	Ref			
Left	5,487	0.878	0.809	0.952	0.002
Unknown	17	0.968	0.327	2.865	0.95
Tumor Histological Type					
Adenocarcinoma	6,880	Ref			
Squamous Cell Carcinoma	4,319	1.182	1.079	1.295	<0.001
Large Cell Carcinoma	566	1.166	0.937	1.451	0.17
Other ^d	708	1.259	1.053	1.505	0.011
Tumor Grade					
1	614	Ref			
2	5,100	1.148	0.944	1.397	0.17
3	5,981	1.103	0.907	1.342	0.32
4	336	0.983	0.702	1.377	0.92
Undetermined	442	1.353	1.021	1.792	0.04
Tumor Pathological Stage					

I	3,073	Ref			
II	5,981	0.798	0.721	0.884	<0.001
III	3,419	0.876	0.782	0.981	0.02
Covariate	N	OR	LCL	UCL	p Value
Tumor Size		1.000	0.999	1.002	0.68
Type of Resection					
Lobectomy	10,833	Ref			
Pneumonectomy	1,640	1.315	1.162	1.489	<0.001
Length of Inpatient Stay					
≤ 14 Days	11,965	Ref			
> 14 Days	508	3.126	2.584	3.782	<0.001
Readmission Within 30 Days of Discharge					
No	11,287	Ref			
Unplanned	435	1.772	1.440	2.179	<0.001
Planned	374	0.523	0.396	0.690	<0.001
Planned and Unplanned	15	1.229	0.397	3.805	0.72
Unknown	362	1.188	0.935	1.510	0.16

NOS = Not otherwise specified

OR = Odds ratio

LCL = Lower confidence limit

UCL = Upper confidence limit

a = Includes Community Cancer Program, Comprehensive Community Cancer Program, Integrated Network Cancer Program and other specified types of cancer programs.

b = Percent of people in the patient's zip code area with no high-school diploma.

c = Based on patient's zip code area.

d = Non-small cell not further defined.